SCHEMBL16237271

SCHEMBL16237271

Cc1sc(C(=O)O)cc1S(=O)(=O)Cl

nearest known ligand 0.55

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
DAO P14920 7/20 0.55
KDM4E B2RXH2 2/20 0.55
MAPT P10636 2/20 0.55
ALDH1A1 P00352 2/20 0.55
MEN1 O00255 1/20 0.55
KMT2A Q03164 1/20 0.55
GPR35 Q9HC97 4/20 0.38
ALOX15 P16050 1/20 0.38
HCAR2 Q8TDS4 1/20 0.36
LMNA P02545 1/20 0.36
MAPK1 P28482 1/20 0.36
GSK3B P49841 1/20 0.36
BCL2L1 Q07817 1/20 0.34
KEAP1 Q14145 1/20 0.33
NFE2L2 Q16236 1/20 0.33
NOTUM Q6P988 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22638717 0.81 DAO (0.55) DAOKDM4EMAPTALDH1A1MEN1
SCHEMBL3060116 0.81 DAO (0.44) DAOKDM4EMAPTALDH1A1MEN1
SCHEMBL2656890 0.80 GAA (0.42) KDM4EMAPTALDH1A1MAPK1
SCHEMBL6964654 0.78 DAO (0.41) DAOKDM4EMAPTALDH1A1MEN1
SCHEMBL8779802 0.76 KDM4E (0.40) DAOKDM4EMAPTALDH1A1MEN1
SCHEMBL2659026 0.75 KMT2A (0.48) DAOKDM4EMAPTALDH1A1MEN1
SCHEMBL28225381 0.74 DAO (0.56) DAOKDM4EMAPTALDH1A1MEN1
SCHEMBL392578 0.74 ALDH1A1 (0.52) KDM4EMAPTALDH1A1MEN1KMT2A
SCHEMBL10590843 0.72 CDK1 (0.41) KDM4EALDH1A1
SCHEMBL7816128 0.72 DAO (0.63) DAOKDM4EMAPTALDH1A1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-105960400-B Sulfamoylthiophene amide derivatives and its purposes for being used to treat hepatitis B as drug 爱尔兰詹森科学公司 2019-05-31 CN disclosed
US-10160743-B2 Sulphamoylthiophenamide derivatives and the use thereof as medicaments for the treatment of hepatitis B JANSSEN SCIENCES IRELAND UC (IE) 2018-12-25 US disclosed
EP-2997019-B1 SULPHAMOYLTHIOPHENAMIDE DERIVATIVES AND THE USE THEREOF AS MEDICAMENTS FOR THE TREATMENT OF HEPATITIS B JANSSEN SCIENCES IRELAND UC (IE) 2018-08-08 EP disclosed
CN-105960400-A Sulphamoylthiophenamide derivatives and the use thereof as medicaments for the treatment of hepatitis b 爱尔兰詹森科学公司 2016-09-21 CN disclosed
US-20160115149-A1 SULPHAMOYLTHIOPHENAMIDE DERIVATIVES AND THE USE THEREOF AS MEDICAMENTS FOR THE TREATMENT OF HEPATITIS B JANSSEN SCIENCES IRELAND UC (IE) 2016-04-28 US disclosed
EP-2997019-A1 SULPHAMOYLTHIOPHENAMIDE DERIVATIVES AND THE USE THEREOF AS MEDICAMENTS FOR THE TREATMENT OF HEPATITIS B Janssen Sciences Ireland UC (IE) 2016-03-23 EP disclosed
WO-2014184365-A1 SULPHAMOYLTHIOPHENAMIDE DERIVATIVES AND THE USE THEREOF AS MEDICAMENTS FOR THE TREATMENT OF HEPATITIS B JANSSEN R&D IRELAND (IE) 2014-11-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10160743-B2 Sulphamoylthiophenamide derivatives and the use thereof as medicaments for the treatment of hepatitis B HBS1L, SLC10A1, NR1H4 DAO 3447/4885KDM4E 1565/4885MAPT 3162/4885
US-20160115149-A1 SULPHAMOYLTHIOPHENAMIDE DERIVATIVES AND THE USE THEREOF AS MEDICAMENTS FOR THE TREATMENT OF HEPATITIS B HBS1L, SLC10A1, NR1H4 DAO 3447/4885KDM4E 1565/4885MAPT 3162/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.